---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-038624"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2026-08-17T11:05:23+00:00"
generated_at: "2026-08-17T11:10:22.234540+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q2 revenue flat at $1.77M; net loss $14.3M on recall charges

## Summary
- Q2 2026 revenue $1.771M, down 0.4% YoY; international up 21% to $2.122M, U.S. negative due to $734K recall credits.
- Net loss $14.324M ($0.17/share) vs $13.151M loss ($0.26/share) in Q2 2025; gross loss $774K incl. $612K inventory impairment.
- Cash and marketable securities $30.4M at June 30, 2026, down from $54.2M at Dec 31, 2025.
- Cost savings actions expected to generate ~$9M annual savings; FDA submissions for CGuard Prime 80 cm and original platform expected later this year.
- CGUARDIANS II 30-day outcomes: 100% device success, no deaths/strokes/MI; CGUARDIANS III enrollment started.

## SEC filing metadata
- accession: 0001493152-26-038624
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2026-08-17T11:05:23+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315226038624/0001493152-26-038624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315226038624/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-038624
- JSON: https://secwatch.observer/filing/0001493152-26-038624.json
- Plain text: https://secwatch.observer/filing/0001493152-26-038624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.